Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies

PurposeThis study sought to describe the changes in immune response to a third dose of either Pfizer's or Moderna's COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics. MethodsThis retrospective cohort study analyzed pre-3V and pos...

Full description

Saved in:
Bibliographic Details
Published in:Journal of patient-centered research and reviews 2022-07, Vol.9 (3), p.149-157
Main Authors: Thompson, Michael A, Hallmeyer, Sigrun, Fitzpatrick, Veronica E., Liao, Yunqi, Mullane, Michael P, Medlin, Stephen C, Copeland, Kenneth, Weese, James L
Format: Article
Language:English
Subjects:
antibody
blood cancer
covid-19
hematology
malignancy
mrna vaccine
Original Research
preventive care
sars-cov-2
seroconversion
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PurposeThis study sought to describe the changes in immune response to a third dose of either Pfizer's or Moderna's COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics. MethodsThis retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus. ResultsAmong 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115 (23.3%) seroconverted to positive from prior negative following the third dose (-/+). The remaining 104 (21.1%) were seronegative both before and after 3V (-/-). No participant was seropositive pre-3V and seronegative post-3V (+/-). Results showed a statistically significant increase in the proportion of seropositivity after receiving a third COVID-19 vaccine (P
ISSN:2330-0698
2330-068X
2330-0698
DOI:10.17294/2330-0698.1952